NCT04087590View on ClinicalTrials.gov

Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient

PHASE2UnknownINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Copd
Interventions
DRUG

Formoterol-glycopyrronium co suspension (PT003)

Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily

Trial Locations (1)

59000

RECRUITING

Hop Calmette Chu Lille, Lille

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University Hospital, Lille

OTHER